Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research

This article was originally published in The Pink Sheet Daily

Executive Summary

With $230 million from industry and NIH, the Accelerating Medicines Partnership will seek to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.

You may also be interested in...



BIO 2014 Wednesday Round-Up: The Search For Innovation

BIO was abuzz on day three of the conference with excitement over keynote speaker Hillary Clinton as her secret service presence was detected even in the early hours of the day. Meanwhile panelists continued to address the hot topics of collaboration, international growth and oncology.

Viebacher: Drug R&D Future Is In Collaboration, But Safe Harbors Needed

Sanofi CEO says firms and other healthcare stakeholders all need to work together, but “no good deed goes unpunished.”

Drug Development Legislation Targeted For Next Year By Rep. Upton

Energy and Commerce Committee chairman outlines a plan to develop legislation to accelerate pharmaceutical “discovery, development and delivery.”

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel